Neuromuscular Neuroimmunological Diseases: Myasthenia Gravis

  • Andrew R. Pachner


Myasthenia gravis (derived from “my”-muscle, “asthenia”-weakness, and “gravis”-severe) is a neuromuscular disease whose clinical hallmark is fatigable muscle weakness caused by autoantibodies to proteins at the neuromuscular junction (NMJ).


Lyme Disease Compound Muscle Action Potential Thymic Hyperplasia Compound Muscle Action Potential Amplitude Myasthenic Crisis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Zhang X, Yang M, Xu J, et al. Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry. Apr 2007;78(4):386–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Brooks EB, Pachner AR, Drachman DB, Kantor FS. A sensitive rosetting assay for detection of acetylcholine receptor antibodies using BC3H-1 cells: positive results in ‘antibody-negative’ myasthenia gravis. J Neuroimmunol. 1990;28(1):83–93.PubMedCrossRefGoogle Scholar
  3. 3.
    Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology. 2003;61(12):1652–61.PubMedGoogle Scholar
  4. 4.
    Pachner AR. Antigen-specific immunotherapy in myasthenia gravis: failed promise and new hope. J Neuroimmunol. 2004;152(1–2):vii–viii.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Andrew R. Pachner
    • 1
  1. 1.Department of Neurology and Neuroscience New Jersey Medical SchoolUniversity of Medicine and Dentistry of New JerseyNewarkUSA

Personalised recommendations